Based on the Allergy Therapeutics stock forecast from 0 analysts, the average analyst target price for Allergy Therapeutics is not available over the next 12 months. Allergy Therapeutics’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Allergy Therapeutics is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Allergy Therapeutics’s stock price was GBX 6.50. Allergy Therapeutics’s stock price has changed by -4.41% over the past week, -7.14% over the past month and +176.60% over the last year.
No recent analyst target price found for Allergy Therapeutics
No recent average analyst rating found for Allergy Therapeutics
Company Overview Allergy Therapeutics
N/A
N/A
N/A
N/A
GBX
UK
Adjusted Closing Price for Allergy Therapeutics (AGY:LSE)
Loading...
Unadjusted Closing Price for Allergy Therapeutics (AGY:LSE)
Loading...
Share Trading Volume for Allergy Therapeutics Shares
Loading...
Compare Performance of Allergy Therapeutics Shares
Frequently Asked Questions About Allergy Therapeutics (AGY:LSE) Stock
Stock Target Advisor's fundamental analysis for Allergy Therapeutics's stock is Bearish.
Unfortunately we do not have enough data on AGY:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AGY:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AGY:LSE's stock to indicate if its overvalued.
The last closing price of AGY:LSE's stock was GBX 6.50.
Unfortunately we do not currently have any market capitalization data for AGY:LSE's stock.
Unfortunately we do not have enough analyst data on AGY:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Allergy Therapeutics's stock.
Sorry, we do not have any data on the number of employees for Allergy Therapeutics.
Sorry we do not have any infomation available on Allergy Therapeutics's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Allergy Therapeutics (AGY:LSE) Stock
Stock Target Advisor's fundamental analysis for Allergy Therapeutics's stock is Bearish.
Unfortunately we do not have enough data on AGY:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AGY:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AGY:LSE's stock to indicate if its overvalued.
The last closing price of AGY:LSE's stock was GBX 6.50.
Unfortunately we do not currently have any market capitalization data for AGY:LSE's stock.
Unfortunately we do not have enough analyst data on AGY:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Allergy Therapeutics's stock.
Sorry, we do not have any data on the number of employees for Allergy Therapeutics.
Sorry we do not have any infomation available on Allergy Therapeutics's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AGY:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
